Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
RBC BioscienceROCO:6848 +4.86%76 EBITDA Margin % is 25.65% as of Dec. 2025, which is 11% above its 10-year median of 23.12. GuruFocus rates ROCO:6848 with a GF Score™ of 76/100 and a GF Value™ of NT$19.91 (Fairly Valued). The stock has 7 warning signs investors should review. Among 939 Biotechnology companies, RBC Bioscience ranks better than 86.79% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. RBC Bioscience's EBITDA for the
six
months ended in Dec. 2025 was NT$28.7 Mil. RBC Bioscience's Revenue for the
six
months ended in Dec. 2025 was NT$112.0 Mil. Therefore, RBC Bioscience's EBITDA margin for the quarter that ended in Dec. 2025 was 25.65%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
RBC Bioscience EBITDA Margin % Related Terms
RBC Bioscience EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for RBC Bioscience's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6848 vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, RBC Bioscience's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RBC Bioscience EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, RBC Bioscience's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where RBC Bioscience's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RBC Bioscience (ROCO:6848) has a EBITDA Margin % of 25.65% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on RBC Bioscience and its competitors. This is 11% above median its historical median of 23.12. Over the past decade, RBC Bioscience's EBITDA Margin % has ranged from 17.91 to 33.44. According to the industry distribution chart, RBC Bioscience ranks #124 out of 939 companies in the Biotechnology industry, placing it in the top 13.2%.
Is RBC Bioscience's EBITDA Margin % too high?
RBC Bioscience's current EBITDA Margin % of 25.65% is 11% above median its 10-year median of 23.12. Over the past 10 years, this metric has ranged from a low of 17.91 to a high of 33.44. Based on the distribution chart, RBC Bioscience ranks #124 out of 939 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, RBC Bioscience has a GF Score™ of 76/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does RBC Bioscience's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, RBC Bioscience ranks #124 out of 939 companies for EBITDA Margin %. This places RBC Bioscience in the top 13% of its industry — outperforming the majority of peers. Historically, RBC Bioscience's own EBITDA Margin % has ranged from 17.91 to 33.44 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on RBC Bioscience and its competitors. RBC Bioscience's current EBITDA Margin % is 25.65%, which is 11% above median its own 10-year median of 23.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RBC Bioscience stock overvalued right now?
Based on GuruFocus' analysis, RBC Bioscience (ROCO:6848) is currently considered Fairly Valued. The stock's GF Value™ is NT$19.91, compared to a current price of NT$20.50 — trading 3% above its estimated fair value. The current EBITDA Margin % is 25.65%, which is 11% above median its 10-year median of 23.12. RBC Bioscience's overall GF Score™ is 76/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For RBC Bioscience (ROCO:6848), the current EBITDA Margin % is 25.65% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is RBC Bioscience (ROCO:6848) Overvalued in 2026?
Based on GuruFocus' analysis, RBC Bioscience stock appears to be overvalued.
The current stock price of NT$20.50 is trading 3% above its estimated GF Value™ of NT$19.91.
GuruFocus considers RBC Bioscience to be Fairly Valued.
Key valuation signals for ROCO:6848:
EBITDA Margin %: 25.65% (11% above median its 10-year median of 23.12)
GF Value™: NT$19.91 vs. price of NT$20.50 (3% above fair value)
No single metric tells the full story. See the ROCO:6848 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
RBC Bioscience Corp is a bio-sciences company. Its products include the manufacture and sale of molecular biological medical diagnosis and research reagents, gene extraction automatic testing instruments, and gene extraction reagent tissues.
76GF Score
Get the complete analysis for ROCO:6848
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6848 has been successfully added to your 
